Article Text

Download PDFPDF
Original article
Cilostazol attenuates on-treatment platelet reactivity in patients with CYP2C19 loss of function alleles receiving dual antiplatelet therapy: a genetic substudy of the CILON-T randomised controlled trial
  1. Kyung Woo Park,
  2. Jin Joo Park,
  3. Seung-Pyo Lee,
  4. Il-Young Oh,
  5. Jung-Won Suh,
  6. Han-Mo Yang,
  7. Hae-Young Lee,
  8. Hyun-Jae Kang,
  9. Young-Suk Cho,
  10. Bon-Kwon Koo,
  11. Tae-Jin Youn,
  12. In-Ho Chae,
  13. Dong-Ju Choi,
  14. Byung-Hee Oh,
  15. Young-Bae Park,
  16. Hyo-Soo Kim
  1. Cardiovascular Center, Seoul National University Main and Bundang Hospital, Seoul, Korea
  1. Correspondence to Dr Hyo-Soo Kim, Department of Internal Medicine and Cardiovascular Center, Seoul National University Hospital, 28 Yongon-dong Chongno-gu, Seoul 110-744, Korea; hyosoo{at}


Objective To evaluate whether the addition of cilostazol to dual antiplatelet therapy (DAT, aspirin plus clopidogrel) can attenuate clopidogrel on-treatment platelet reactivity (OPR) in patients with the CYP2C19 loss-of-function (LOF) allele.

Methods In the CILON-T randomised trial, patients were randomly assigned to either DAT or triple antiplatelet therapy (TAT, DAT plus cilostazol). Genotyping of cytochrome P450 CYP2C19 *2, *3 and *17 was performed and OPR was measured using the VerifyNow P2Y12 assay. Carriers were those with at least one CYP2C19 LOF allele.

Results 474 patients were enrolled; 236 received DAT, 238 TAT. Mean OPR was significantly lower in the TAT compared with the DAT group (207±5 vs 236±5, p<0.001, P2Y12 reaction units, PRU). When grouped according to the presence of the CYP2C19 LOF allele, mean OPR was significantly lower in the TAT compared with the DAT group in only carriers of the LOF allele and not non-carriers (213±6 vs 256±7 PRU, p<0.001 in carriers, 196±9 vs 211±8 PRU, p=0.242 in non-carriers for TAT vs DAT, respectively). The proportion of patients with high OPR was highest in carriers receiving DAT (60.8%) compared with the other three groups. On multivariate analysis, carriers on DAT was an independent predictor of high OPR (OR 2.93, 95% CI 1.64 to 5.21) along with female gender and increasing age.

Conclusion TAT significantly reduced OPR compared with DAT in carriers of the CYP2C19 LOF allele, but not in non-carriers. These data suggest that the addition of cilostazol to DAT may be a good strategy to attenuate CYP2C19 LOF-related high OPR.

  • Antiplatelet treatment
  • cilostazol
  • clopidogrel
  • CYP2C19 loss-of-function alleles
  • genetics
  • on-treatment platelet reactivity

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • The first two authors contributed equally to this study.

  • Funding This study was supported by a grant from the Clinical Research Center for Ischemic Heart Disease, Seoul, Republic of Korea (0412-CR02-0704-0001) and a grant from the Innovative Research Institute for Cell Therapy, Seoul National University Hospital (A062260), sponsored by the Ministry of Health, Welfare and Family, Republic of Korea.

  • Competing interests None to declare.

  • Patient consent Obtained.

  • Ethics approval This study was conducted with the approval of the institutional review board of Seoul National University Hospital.

  • Provenance and peer review Not commissioned; externally peer reviewed.